Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Association Between Lipoprotein(a) and Risk Factors of Atherosclerosis in Russian Population (Data of Observational ESSE-RF study)

https://doi.org/10.20996/1819-6446-2019-15-5-612-621

Full Text:

Abstract

Experimental and clinical data indicate a significant contribution of lipoprotein(a) (Lp[a]) to the atherogenesis. However, the pathophysiological mechanisms of this relationship are not fully understood.

Aim. To investigate the distribution of Lp(a) in the population of the regions participating in the Study “Epidemiology of Cardiovascular Diseases in the Regions of the Russian Federation” (ESSE-RF) and to evaluate its associations with cardiovascular risk factors.

Material and methods. Representative samples of the male and female population of 7 regions of the Russian Federation, aged from 25 to 64 years, enrolled in the multi-center cross-sectional epidemiological study were analyzed. A total of 10332 people were examined, of whom 3732 were men (36.0%) and 6600 were women (64.0%), the average age was equal in both sexes.

Results. The mean value of Lp(a) reached 22.4 mg/dl (standard deviation 21.3 mg/dl) and significantly differed from the median (11.1 mg/dl; interquartile range from 3.9 to 20.2 mg/dl), forming the right-skewed distribution in both male and female population. Lp(a) levels were statistically significantly correlated with the level of low-density lipoproteins cholesterol (LDL-C), ароВ/аpoAI and total cholesterol. Notably, the odds ratios were growing by quintiles, and increased along with increasing lipid values (p<0.0001). Lp(a) levels were also positively associated with high-sensitivity C-reactive protein (hs-CRP) and negatively correlated with blood concentration of glucose and triglycerides (TG). There were no associations with body mass index, waist circumference and smoking status.

Conclusion. According to the ESSE-RF data, there are significant positive associations of Lp(a) with the LDL-C level, the ароВ/аpoAI ratio, total cholesterol, and hs-CRP. Negative associations are established with glucose and TG levels. The future studies should be planned with the notion of the Lp(a)’s right-skewed distribution type. 

About the Authors

S. A. Shalnova
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Professor, Head of Department of Epidemiology of Chronic Non-Communicable Diseases, 

Petroverigsky per. 10, Moscow, 101990



M. V. Ezhov
National Medical Research Center of Cardiology
Russian Federation

MD, PhD, Leading Researcher, Department of Atherosclerosis,

Tretya Cherepkovskaya ul. 15а, Moscow, 121552



V. A. Metelskaya
National Medical Research Center for Preventive Medicine
Russian Federation

PhD (in Biology), Professor, Head of Department of Biochemical Markers of Chronic Non-Communicable Diseases Risk, 

Petroverigsky per. 10, Moscow, 101990



S. E. Evstifeeva
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Senior Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases,

Petroverigsky per. 10, Moscow, 101990



V. I. Tarasov
National Medical Research Center for Preventive Medicine
Russian Federation

PhD (in Biology), Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases,

Petroverigsky per. 10, Moscow, 101990



G. A. Muromtseva
National Medical Research Center for Preventive Medicine
Russian Federation

PhD (in Biology), Leading Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases,

Petroverigsky per. 10, Moscow, 101990



Yu. A. Balanova
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Leading Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases,

Petroverigsky per. 10, Moscow, 101990



A. E. Imaeva
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Senior Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases, 

Petroverigsky per. 10, Moscow, 101990



A. V. Kapustina
National Medical Research Center for Preventive Medicine
Russian Federation

MD, Senior Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases,

Petroverigsky per. 10, Moscow, 101990



A. A. Shabunova
Institute of Socio-Economic Development of Territories, Russian Academy of Sciences
Russian Federation

PhD (in Economic), Professor, Director, 

Gorkogo ul. 56a, Vologda, 160014



O. A. Belova
Cardiology Clinic
Russian Federation

MD, Head Physician,

Fridriha Engelsa pr. 22, Ivanovo, 153012



I. A. Trubacheva
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences
Russian Federation

MD, PhD, Head of the Department of Population Cardiology with a Group of Scientific and Medical Information, Patent Science and International Relations,

Kievskaya ul. 111a, Tomsk, 634012



A. Y. Efanov
Tyumen State Medical University
Russian Federation

MD, PhD, Associate Professor, Chair of Preventive and Restorative Medicine,

Odesskaya ul. 54, Tyumen, 625023



Z. T. Astakhova
North Ossetia State Medical Academy
Russian Federation

MD, PhD, Professor, Head of Chair of Hospital Therapy, 

Pushkinskaya ul. 40, Vladikavkaz, 362019



N. V. Kulakova
Pacific State Medical University
Russian Federation

MD, PhD, Associate Professor, Institute of Therapy and Instrumental Diagnostics,

Ostryakova pr. 2, Vladivostok, 690002



S. A. Boytsov
National Medical Research Center of Cardiology
Russian Federation

MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director,

Tretya Cherepkovskaya ul. 15а, Moscow, 121552



O. M. Drapkina
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director, 

Petroverigsky per. 10, Moscow, 101990



References

1. Tsimikas S., Hall J.L. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60:716-21. DOI:10.1016/j.jacc.2012.04.038.

2. Dubé J.B., Boffa M.B., Hegele R.A., Koschinsky M.L. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012;23:133-40. DOI:10.1097/MOL.0b013e32835111d8.

3. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082-5. DOI:10.1161/01.cir.102.10.1082.

4. O’Donoghue M., Morrow D.A., Tsimikas S., et al. Lipoprotein (a) For Risk Assessment in Patients with Established Coronary Artery Disease. J Am Coll Cardiol. 2014;63(6):520-7. DOI:10.1016/j.jacc.2013.09.042.

5. Willeit P., Kiechl S., Kronenberg F., et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64(9):851-60. DOI:10.1016/j.jacc.2014.03.061.

6. Nordestgaard B.G., Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57(11):1953-75. DOI:10.1194/jlr.R071233.

7. Lim T.S., Yun J.S., Cha S.A., et al. Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study. Korean J Intern Med. 2016;31:1110-9. DOI:10.3904/kjim.2016.030.

8. Ezhov M.V., Safarova M.S., Matchin Y.G., et al. Association of high levels lipoprotein(a) with coronary artery potency during the first year after percutaneous coronary interventions. Clinician. 2011;1:18- 24 (In Russ.)

9. Ezhov M.V., Safarova M.S., Afanasieva J.I., et al. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis 2014; 235 (2): 477-482. DOI: 10.1016/j.atherosclerosissup.2017.05.011.

10. Alexandrovitch O.V., Perova N.V., Deev A.D., et al. Serum lipoprotein(a) level in subjects free of clinical manifestations of atherosclerosis-related diseases: the relationship with lipid and glucose metabolism parameters and arterial stiffness. Atherosclerosis. 2019;15(1):5-15 (In Russ.) DOI:10.15372/ATER20190101.

11. Scientific and Organizing Committee of the Russian Federation essay. The epidemiology of cardiovascular disease in different regions of Russia (ESSE-RF). Rationale and design of the study. Profilakticheskaya Meditsina. 2013;6:25-34 (In Russ.)

12. Waldeyer С., Makarova N., Zeller T., et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017;38(22):2490- 8. DOI:10.1093/eurheartj/ehx166.

13. Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-53. DOI:10.1093/eurheartj/ehq386.

14. Ye Zh., Haycock P.C., Gurdasani D., et al. The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal? Epidemiological evidence. Diabetes. 2014;63:332-42. DOI:10. 2337/db13-1144.


For citation:


Shalnova S.A., Ezhov M.V., Metelskaya V.A., Evstifeeva S.E., Tarasov V.I., Muromtseva G.A., Balanova Y.A., Imaeva A.E., Kapustina A.V., Shabunova A.A., Belova O.A., Trubacheva I.A., Efanov A.Y., Astakhova Z.T., Kulakova N.V., Boytsov S.A., Drapkina O.M. Association Between Lipoprotein(a) and Risk Factors of Atherosclerosis in Russian Population (Data of Observational ESSE-RF study). Rational Pharmacotherapy in Cardiology. 2019;15(5):612-621. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-5-612-621

Views: 29


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)